Additionally, the development of targeted therapies directed to tumor cells harboring ESR1 mutations is a logical and appealing concept, and extensive preclinical research has been conducted in this field (4, 21), and promising work evaluating treatment with new generation endocrine agents is in progress (22, 23). The gene discussed is ESR1; the disease is neoplasm.